# OnCo record rejuv-frontier-unlicensed-peptides (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-frontier-unlicensed-peptides/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-frontier-unlicensed-peptides" ;
  schema:name "Unlicensed peptides sold for recovery"@en ;
  schema:description "BPC-157, ipamorelin, thymosin, CJC-1295 and the rest are sold online and by clinics for healing, energy and recovery after treatment. The FDA has placed several of them on the list of substances that may present significant safety risks in compounding, and names immunogenicity, impurities and, for some, deaths in studies."@en ;
  schema:url <https://onco.cc/technologies/rejuv-frontier-unlicensed-peptides/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Growth_hormone_secretagogue> ;
  schema:citation <https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks> ;
  onco:status "preclinical" ;
  onco:tag "rejuvenation", "survivorship", "evidence:harm", "unproven", "regulator-warning" ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/alternative-medicine-instead-of-treatment/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/> .